![]() Microbot currently intends to use the net proceeds from this offering for the continuous development and regulatory activities for its SCS device for the treatment of hydrocephalus and NPH continue the development of the Company’s LIBERTY robotic system, including its expansion through addition of complementary assets to it either through internal development, in-license or acquisitions expand and develop additional applications deriving from its existing IP portfolio, either through internal development, in-license or acquisition and for working capital and other general corporate purposes. The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $10 million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |